Document is current

Any future updates will be listed below

Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

Crossref DOI link: https://doi.org/10.1007/s00280-021-04342-x

Published Online: 2021-09-24

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark